To achieve preferential delivery of IL-2-engineered protein into tumor cells and the TME, researchers have developed CEA-IL2v (termed cergutuzumab amunaleukin)89 and FAP-IL2v (termed Simulkafusp alfa)90, which are immunocytokines comprising IL-2v and an Ab against CEA and FAP, respectively. The gene discussed is FAP; the disease is neoplasm.